Ecuador Normative Codes and Sources: WHO, GHTF, IMDRF, IEC and Device Coding

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Article 20 of the new regulation defines, for the first time in a dedicated article, the 4 categories of sources for normative documents (codigos normativos): WHO guidelines or technical reports, GHTF and IMDRF documents, the classification instructivos issued by ARCSA, and official documents issued by other international reference regulatory agencies. This article resolves the long-standing question of which standards may be cited as technical bases, and it draws the boundary of the technical evidence ARCSA will accept.

2. Legal basis

Regulation	Reference number	Publication date	Articles
Substitute Technical Health Regulation for the Health Registration, Control and Surveillance of Medical Devices for Human Use	Resolucion ARCSA-DE-2026-003-DASP	Signed 2026-04-28	Article 20 (sources of normative documents, 4 categories)
Same as above	Same as above	Same as above	General provision TERCERA (classification follows GHTF and IMDRF rules), general provision CUARTA (UMDNS and GMDN coding)
Same as above	Same as above	Same as above	Article 3 (definitions of GMDN, UMDNS, ECRI, IEC, GHTF, IMDRF and IA), Article 4 (abbreviation table)

3. Expert insights

Insight one: Article 20 lifts standards out of the registration requirements into a citable external system. Earlier submission requirements were a closed, item-by-item list; Article 20 builds a structure of open enumeration bounded by four sources. Companies may cite international documents within the list as technical argumentation, but citing documents outside the list requires additional argument on their acceptability.

Insight two: GHTF and IMDRF are listed side by side, reflecting continuity. GHTF, the Global Harmonization Task Force, has been succeeded by IMDRF, yet Article 20 (b) and the definitions in Article 3 retain both. This has practical value: legacy technical dossiers built on GHTF-era documents can still be cited and need not be rewritten wholesale into IMDRF versions.

Insight three: IEC standards enter the system through the Article 3 definitions. Article 3 defines IEC, the International Electrotechnical Commission, describing its documents as helping designers and manufacturers ensure the safety, reliability and efficiency of devices. Electrical safety argumentation for active devices should cite the IEC 60601 series first, and conformity certificates should be submitted under item 2.7 of Article 24.

Insight four: the official documents of other international reference regulatory agencies under item (d) are the most flexible source. It echoes the highly regulated agencies concept of Article 31 and opens a citation route for technical documentation already held from FDA, EMA, Health Canada, TGA and ANVISA, among others. However, the wording of item (d) is official documents, and it does not cover statements issued by third-party certification bodies or consultancies.

Insight five: general provision CUARTA brings coding systems into the normative framework as well, and it governs nomenclature rather than barcodes. Device codes used for traceability should follow internationally recognized systems: UMDNS, developed by ECRI, and GMDN. If neither system offers a matching code, the manufacturer may, as an exception, use alternative nomenclature published by a highly regulated health agency or referenced by WHO. The provision governs naming and coding and does not require any specific barcode system.

Correction note: some Chinese and English materials claim that the new Ecuadorian regulation mandates GS1 barcodes with batch-level traceability. A full-text search of the complete 48-page original shows that GS1 appears 0 times. The traceability provisions are general provision CUARTA (UMDNS and GMDN naming and coding) and Article 68 (identification cards for implantable devices). No draft may state a GS1 mandatory requirement.

4. Practical recommendations

Build a ledger of cited technical documents, tagging each with its category under Article 20.
Cite IMDRF documents first: GHTF-era documents may continue in use, but the corresponding IMDRF documents should be added.
Ground the electrical safety argumentation of active devices in the IEC 60601 series, stating the standard version explicitly in the dossier.
Restrict citations of foreign agency documents to official documents: statements from third-party bodies do not stand as independent bases.
Use UMDNS or GMDN for product coding: where no code exists, apply the exception nomenclature under general provision CUARTA and state the reasons.

5. Verification checklist

□ A ledger of cited technical documents has been built and each entry tagged with its Article 20 source category
□ Cited IMDRF and GHTF documents have been checked as current versions
□ IEC 60601 series conformity evidence has been prepared for active devices
□ All foreign agency documents cited are officially issued
□ Products have obtained UMDNS or GMDN codes, or exception nomenclature justifications have been prepared
□ The versions of all cited standards are stated explicitly in the technical documentation

Regulatory information verified as of October 29, 2026

GRZAN core service lines

Global registration access: EU CE (MDR/IVDR), US FDA (510(k)/De Novo/PMA), UK UKCA, Australia TGA, Canada Health Canada, Brazil ANVISA and Russia RZN, together with pre-market registration pathway planning and submission execution across Latin America, Southeast Asia and the Middle East.
Authorized representative services: EU EC REP, UK RP, Swiss CH REP, Australian sponsor and US Agent holding and representation services, with support for neutral license-holder structures.
Quality system compliance: ISO 13485 establishment and maintenance, MDSAP audit preparation, GMP conformity coaching, and technical documentation (TD) drafting and remediation.
Clinical and evaluation support: clinical evaluation plans (CEP) and reports (CER), equivalence argumentation, PMCF planning and execution, and IVD performance evaluation.
Post-market compliance: vigilance and adverse event reporting, FSCA and recall execution, registration change and renewal management, and maintenance of national regulatory databases.

Why manufacturers choose GRZAN

Local regulatory teams: target-market work is performed by locally licensed regulatory professionals, and submission dossiers are written directly in the local official language without secondary translation.
Neutral license-holder structures: GRZAN offers holding arrangements that are not tied to any distribution channel, preventing registration certificates from being locked in by channel partners.
Regional leverage: one technical dossier can be reused across Andean Community and Mercosur member states, spreading regional compliance costs.
Full lifecycle support: from classification determination and pathway design through dossier preparation, license holding, customs clearance, post-market vigilance and renewal.

Contact

GRZAN provides registration support in Ecuador for manufacturers, importers and authorized representatives.
Email: info@grzanglobal.com
Service inquiries: Ecuador and Andean market registration plans, license-holder structure design, official fee and timeline estimation

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.